Evaluating the Safety and Efficacy of the Maurora® DES in ICAS

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 156 participants.

Also called NCT05719883

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 156 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05719883
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05719883. Randomized; single masking; primary purpose treatment. Start 2023-02-20 (actual); primary completion 2025-04-30 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evaluating the Safety and Efficacy of the Maurora® DES in ICAS
Acronym
Maurora ICAS
Condition
Intracranial Arteriosclerosis
Condition
Stroke (CVA) or TIA (transient ischemic attack)
Intervention (Device)
Maurora® Sirolimus Eluting Stent System
Intervention (Device)
APOLLO™ Intracranial Stent System
Lead sponsor
Beijing Tiantan Hospital (class: other)
Collaborator
Alain Medical (Beijing) Co., Ltd. (class: not stated)

Record details

Record id
cardio:ct-nct05719883
Content hash
14a740be332f88cff6b12c4cb56a5262ed28906dfcc6b0e2021e82819c467520